TY - JOUR
T1 - Improved left ventricular function after growth hormone replacement in patients with hypopituitarism
T2 - Assessment with radionuclide angiography
AU - Cuocolo, Alberto
AU - Nicolai, Emanuele
AU - Colao, Annamaria
AU - Longobardi, Salvatore
AU - Cardei, Stefania
AU - Fazio, Serafino
AU - Merola, Bartolomeo
AU - Lombardi, Gaetano
AU - Saccà, Luigi
AU - Salvatore, Marco
PY - 1996
Y1 - 1996
N2 - Prolonged growth hormone deficiency (GHD) leads to marked cardiac dysfunction; however, whether reversal of this abnormality may be achieved after specific replacement therapy has not yet been completely clarified. Fourteen patients with childhood-onset GHD (nine men and five women, mean age 27 ± 4 years) and 12 normal control subjects underwent equilibrium radionuclide angiography under control conditions at rest. Patients with GHD were also studied 6 months after recombinant human (rh) GH treatment (0.05 IU/kg per day). Normal control subjects and patients with GHD did not differ with respect to age, gender and heart rate. In contrast, left ventricular ejection fraction (53% ± 9% vs 66% ± 6%, P <0.001), stroke volume index (41 ± 11 vs 51 ± 8 ml/m2, P <0.01) and cardiac index (2.8 ± 0.6 vs 3. ± 0.5 l/min/m2, P <0.001) were significantly lower in GHD patients than in normal control subjects. None of the GHD patients showed adverse or side-effects during rhGH therapy; thus none required a reduction in GH dose during the treatment period. Heart rate and arterial blood pressure were not significantly modified by rhGH treatment. After 6 months of rhGH therapy a significant improvement in left ventricular ejection fraction (from 53% ± 9% to 59% ± 9%, P <0.01), stroke volume index (from 41 ± 11 to 47 ± 13 ml/m2, P <0.05) and cardiac index (from 2.8 ± 0.6 to 3.3 ± 0.8 l/min/m2, P <0.01) was observed in GHD patients. In conclusion, prolonged lack of GH leads to impaired left ventricular function at rest. Reversal of this abnormality may be observed after 6 months of specific replacement therapy in patients with childhood-onset GHD.
AB - Prolonged growth hormone deficiency (GHD) leads to marked cardiac dysfunction; however, whether reversal of this abnormality may be achieved after specific replacement therapy has not yet been completely clarified. Fourteen patients with childhood-onset GHD (nine men and five women, mean age 27 ± 4 years) and 12 normal control subjects underwent equilibrium radionuclide angiography under control conditions at rest. Patients with GHD were also studied 6 months after recombinant human (rh) GH treatment (0.05 IU/kg per day). Normal control subjects and patients with GHD did not differ with respect to age, gender and heart rate. In contrast, left ventricular ejection fraction (53% ± 9% vs 66% ± 6%, P <0.001), stroke volume index (41 ± 11 vs 51 ± 8 ml/m2, P <0.01) and cardiac index (2.8 ± 0.6 vs 3. ± 0.5 l/min/m2, P <0.001) were significantly lower in GHD patients than in normal control subjects. None of the GHD patients showed adverse or side-effects during rhGH therapy; thus none required a reduction in GH dose during the treatment period. Heart rate and arterial blood pressure were not significantly modified by rhGH treatment. After 6 months of rhGH therapy a significant improvement in left ventricular ejection fraction (from 53% ± 9% to 59% ± 9%, P <0.01), stroke volume index (from 41 ± 11 to 47 ± 13 ml/m2, P <0.05) and cardiac index (from 2.8 ± 0.6 to 3.3 ± 0.8 l/min/m2, P <0.01) was observed in GHD patients. In conclusion, prolonged lack of GH leads to impaired left ventricular function at rest. Reversal of this abnormality may be observed after 6 months of specific replacement therapy in patients with childhood-onset GHD.
KW - Cardiac performance
KW - Growth hormone deficiency
KW - Radionuclide ventriculography
UR - http://www.scopus.com/inward/record.url?scp=9244241551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244241551&partnerID=8YFLogxK
U2 - 10.1007/BF01247366
DO - 10.1007/BF01247366
M3 - Article
C2 - 8612658
AN - SCOPUS:9244241551
VL - 23
SP - 390
EP - 394
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 4
ER -